. Author manuscript; available in PMC: 2007 Nov 1.

Published in final edited form as: Am J Ophthalmol. 2006 Nov;142(5):800–810. doi: 10.1016/j.ajo.2006.06.052

Table 5.

LOCS III Grading by Randomization Group: Worse Eye

	Observation (Mean ± SD) N = 506	Medication (Mean ± SD) N = 511	P- Value^*
Median Duration of Medication (yrs)	1.2	8.5
Nuclear Color (scale 0.1–6.9)	2.66 ± 1.4	2.69 ± 1.4	0.66
Nuclear Opalescence (scale 0.1–6.9)	2.42 ± 1.1	2.46 ± 1.2	0.51
Cortical Opacity (scale 0.1–5.9)	1.23 ± 1.2	1.27 ± 1.3	0.61
Posterior Subcapsular Opacity (scale 0.1–5.9)	0.45 ± 0.7	0.54 ± 0.8	0.054

Multivariate model utilized one LOCS III grading per participant and adjusted for age, race, use of topical medication prior to OHTS, diabetes mellitus, and use of steroids. Models with these same covariates and history of smoking yielded nearly identical results.